Kringle Pharma, Inc. (TYO:4884)
Japan flag Japan · Delayed Price · Currency is JPY
510.00
-64.00 (-11.15%)
Nov 18, 2026, 11:10 AM JST

Kringle Pharma Income Statement

Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
442728069391
Revenue Growth
513.89%-10.00%15.94%-82.35%35.29%
Cost of Revenue
71---88
Gross Profit
371728069303
Selling, General & Admin
1,185300254242196
Research & Development
-681643716533
Operating Expenses
1,185981897958729
Operating Income
-814-909-817-889-426
Interest & Investment Income
1----
Currency Exchange Gain (Loss)
-1---21
Other Non Operating Income (Expenses)
3-6623675
EBT Excluding Unusual Items
-811-915-755-853-330
Gain (Loss) on Sale of Investments
-1----
Pretax Income
-812-915-755-853-330
Income Tax Expense
11111
Net Income
-813-916-756-854-331
Net Income to Common
-813-916-756-854-331
Net Income Growth
-----
Shares Outstanding (Basic)
87655
Shares Outstanding (Diluted)
87655
Shares Change
12.92%6.92%18.72%11.00%16.91%
EPS (Basic)
-105.23-133.88-118.14-158.44-68.16
EPS (Diluted)
-105.23-133.88-118.14-158.44-68.16
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Gross Margin
83.94%100.00%100.00%100.00%77.49%
Operating Margin
-184.16%-1262.50%-1021.25%-1288.41%-108.95%
Profit Margin
-183.94%-1272.22%-945.00%-1237.68%-84.66%
EBIT
-814-909-817-889-426
EBIT Margin
-184.16%----108.95%